Overview

• BioLineRx reports Q3 net loss of $1 mln, narrower than $5.8 mln loss in year-ago quarter

• Company says joint venture plan with Hemispherian to advance GLIX1 cancer therapeutic was a Q3 highlight

• BioLineRx maintains cash runway guidance into first half of 2027

Outlook

• BioLineRx plans to start Phase 1/2a trial for GLIX1 in Q1 2026

• Company maintains cash runway guidance into first half of 2027

• Patent for GLIX1 extends protection until 2040

Result Drivers

• RESEARCH COSTS DROP - R&D expenses decreased 33% mainly on licensing of U.S. motixafortide right to Ayrmid and lower payroll costs after headcount reduction

• LOWER EXPENSES - Sales and marketing costs fell mainly due to shutdown of U.S. commercial operations in Q4 2024 after Ayrmid licensing deal and a drop in G&A costs

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for BioLine RX Ltd is $26.00, about 87.5% above its November 21 closing price of $3.25

Press Release: ID:nPnbvftJMa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)